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Background: 18F-FDG PET/CT (PET) is useful in assessing inflammatory activity in sarcoidosis. However, no
appropriate indications are available. The aim of this study was to develop a prediction rule that can be used to
identify symptomatic sarcoidosis patients who have a high probability of PET-positivity.
Methods: We retrospectively analyzed a cohort of sarcoidosis patients with non organ specific persistent disabling
symptoms (n = 95). Results of soluble interleukin-2 receptor (sIL-2R) assessment and high-resolution computed
tomography (HRCT) were included in the predefined model. HRCT scans were classified using a semi-quantitative
scoring system and PET findings as positive or negative, respectively. A prediction model was derived based on
logistic regression analysis. We quantified the model’s performance using measures of discrimination and
calibration. Finally, we constructed a prediction rule that should be easily applicable in clinical practice.
Results: The prediction rule showed good calibration and good overall performance (goodness-of-fit test, p = 0.78,
Brier score 20.1%) and discriminated between patients with positive and negative PET findings (area under the
receiver-operating characteristic curve, 0.83). If a positive predictive value for the presence of inflammatory activity
of ≥90% is considered acceptable for clinical decision-making without referral to PET, PET would be indicated in
only 29.5% of the patients. Using a positive predictive value of 98%, about half of the patients (46.3%) would
require referral to PET.
Conclusions: The derived and internally validated clinical prediction rule, based on sIL-2R levels and HRCT scoring
results, appeared to be useful to identify sarcoidosis patients with a high probability of inflammatory activity. Using
this rule may enable a more effective use of PET scan for assessment of inflammatory activity in sarcoidosis.
Keywords: Clinical prediction rule, High-resolution computed tomography, Soluble interleukin-2 receptor, PET,
SarcoidosisIntroduction
Sarcoidosis is a multisystemic disease characterized by
cellular immunity activity with formation of noncaseating
granuloma in various organ systems [1,2]. Assessing the
presence of inflammatory activity is important for the
management of sarcoidosis and for the follow-up of treatment
effect [3–5]. Unlike acute sarcoidosis [6,7], assessment of* Correspondence: m.drent@maastrichtuniversity.nl
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reproduction in any medium, provided the orinflammatory activity in sarcoidosis patients with persistent
disabling symptoms that cannot be explained from the
results of routine investigations, including the absence
of lung functional or chest radiographic deterioration,
remains a challenge to clinicians [8–10]. In these patients,
it is often complicated to differentiate between reversible
and irreversible disease. Symptoms like fatigue can be
nonspecific and difficult to objectify [11–14]. Further-
more, symptoms like coughing and dyspnea might be
related to ongoing inflammatory activity as well as to end-
stage disease, i.e. pulmonary fibrosis. In this respect, it
is important to know about the presence or absence of
inflammatory activity, as fibrosis itself is irreversible. In
general, immunosuppressive treatment does not seemsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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flammatory activity [11].
Inflammatory activity is characterized by ongoing T-
cell and macrophage activity and granuloma formation,
reflected by an increase in serological markers of inflamma-
tory activity, i.e. angiotensin-converting enzyme (ACE),
soluble interleukin-2 receptor (sIL-2R) and neopterin,
or abnormalities of glucose metabolism [7,15,16].
18 F-FDG PET/CT (PET) is used to detect high glucose
metabolism and has been shown to be useful for the as-
sessment of inflammatory activity in sarcoidosis [7,17–22].
Previous studies found that elevated serological inflamma-
tory markers, abnormalities on high-resolution computed
tomography (HRCT) and impaired lung function were
associated with PET-positivity [7,8,23,24]. In addition,
diffusely increased metabolic activity in the lung paren-
chyma was found to predict a future deterioration of
diffusion capacity for carbon monoxide (DLCO) when
untreated [24].
It is important to gain knowledge and understanding
about the appropriate use of this new technique for
assessment of inflammatory activity in clinical practice
[21,22]. This means that, in view of the radiation dose and
costs, defining appropriate indications for PET-scanning is
vital. Therefore, the aim of this study was to develop a
prediction rule that can be used in clinical practice to
identify symptomatic sarcoidosis patients for whom there
is a high probability that PET will show the presence of
inflammatory activity.
We reviewed the medical records of all sarcoidosis
patients referred to the interstitial lung disease service
(ild care team) of the department of Respiratory Medicine
at the Maastricht University Medical Centre (Maastricht,
The Netherlands), a tertiary referral center, between June
2005 and September 2010. The study included all patients
who underwent laboratory and lung function testing,
HRCT, as well as a PET scan (n= 106). The indication for
performing PET was the presence of non organ specific
disease-related disabling symptoms persisting for at least
one year. Non organ specific persistent disabling symptoms
were defined as the presence of more than one symptom
that had substantial influence on quality of life, and that
could not be explained from the results of routine
investigations, including the absence of lung functional
or chest radiographic deterioration. The symptoms had
to be present for at least one year and included fatigue
(Fatigue Assessment Scale [FAS] ≥22) [25], symptoms
compatible with small fiber neuropathy (SFN; SFN
Screenings List [SFNSL] score ≥11) [26], arthralgia
and/or muscle pain, dyspnea (MRC dyspnea scale ≥3),
exercise intolerance or coughing. Laboratory and lung
function testing were performed within a 2-week interval
before or after the HRCT. PET scans were made within a3-months interval before or after the HRCT, without
changing the therapy during this period. The diagnosis
was based on consistent clinical features and bronchoal-
veolar lavage (BAL) fluid analysis results, according to the
international guidelines. The diagnosis was confirmed
histological, demonstrating noncaseating epitheloid cell
granulomas, in most cases (75%) [1]. Patients with known
co-morbid conditions associated with positive PET findings
were excluded. This meant that five patients with common
variable immunodeficiency (CVID), five patients with
malignancies and one patient with both rheumatoid
arthritis and amyloidosis were excluded. After exclusion
based on these criteria, 95 patients were selected. The
study protocol was approved by the Medical Research
Ethics Committee of the Maastricht University Medical
Centre (MEC number 04.145.11).Laboratory and lung function tests
Serum levels of sIL-2R were analyzed using commercially
available Diaclone ELISA kits (Sanquin, Amsterdam, The
Netherlands) and considered elevated if >3154 pgmL-1.
Other laboratory analysis and lung function tests were
performed as described previously [8].Imaging
Thin-section scans with 1-mm collimation were obtained
at 10-mm intervals through the chest (Somaton Plus,
Siemens, Erlangen, Germany). The scanning parameters
included 137 kVP, 255 mA, and 1-s scanning time. Both
mediastinal (width 400 HU, level 40 HU) and lung
(width 1600 HU, level -800 HU) window images were
obtained. Scans were reconstructed with a high-frequency
reconstruction algorithm.
A whole body 18 F-FDG PET/CT scan was performed
using a GeminiW PET/CT (Philips Medical Systems) scanner
with time-of-flight (TOF) capability and a 64-slice Brilliance
CT scanner. Patients were fasting for at least 6 hours
before the examination. In all patients blood glucose
was measured to ensure that the blood glucose was
below 10 mmolL-1. 18 F-FDG (GE Health, Eindhoven,
The Netherlands) was injected intravenously and followed
by physiologic saline (10 mL). The injected total activity
of FDG depended on the weight of the patient. Mean
injected dose was: 200 MBq. After a resting period of
45 minutes (time needed for uptake of FDG) PET and
CT images were acquired from the head to the feet. A
low-dose CT scan was performed without intravenous
contrast and was used for attenuation correction of
the PET images. The PET images were acquired in 5-
minute bed positions. The complete PET data set was
reconstructed iteratively with a reconstruction increment
of 5 mm to provide isotropic voxel.
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An experienced thoracic radiologist (JV), blinded to the
patient’s clinical history and to the PET findings, classified
the scans of both lungs using a semi-quantitative HRCT
scoring system that has been described by Oberstein et al.
[27] and that has been used in previous studies by our
group (a detailed description of this scoring system is
shown in the Appendix) [28].
All PET scans were interpreted by an experienced nuclear
medicine physician (MvK), blinded to the patient’s clinical
history and to the HRCT findings. PET findings in the
lungs, lymph nodes, or other soft tissues or bones were
scored as either positive or negative. A positive PET
scan interpretation was performed visually, with a
threshold standardized uptake value (SUVmax) ≥2.5.
18 F-FDG uptake was quantified by drawing a region of
interest around the area of pathology of the co-registered
transaxial slice. SUVmax was calculated as the maximal
pixel activity within the region of interest.
Inter-reader reliability of both the total HRCT score
and the simple PET classification system had already
demonstrated good agreement in the above-mentioned
studies with the same observers (with weighted kappa
values of 0.99 and 1.00, respectively) [8,28]. Accordingly,
a single radiologist and a single nuclear physician were
regarded as sufficient in the present study.Potential predictors
Because of the limited number of patients with a negative
PET scan (the least frequent outcome in this study) and
the usual recommendation to include one predictor for at
least ten events, we had to select the two predictors with
the strongest associations with PET-positivity [29]. Based
on the results of recent studies, the following clinical
characteristics were selected in view of their association
with PET-positivity: elevated serological inflammatory
markers (sIL-2R and neopterin), HRCT abnormalities
as assessed by the HRCT scoring system, and lung function
tests (forced vital capacity (FVC), DLCO) [8,23]. Of the
serological inflammatory parameters, positive sIL-2R had
shown the strongest association with PET-positivity in the
previous study [8]. Neopterin was not added as predictor
since neopterin values were missing in almost half of the
studied patients. Moreover, from a practical point of
view sIL-2R also is preferable considering that in clinical
practice accessibility to neopterin measurement is less
compared to sIL-2R. Lung function tests and HRCT
scoring results were strongly associated with each other
[23] and we decided to include the total HRCT score.
In the end, therefore, two potential predictor variables
(sIL-2R and total HRCT scoring results) were included
in the predefined model.Model development
Missing values were imputed using regression imputation,
since the omission of patients who have one or more
predictor variables missing from the analysis can cause
a considerable loss of precision and may bias results
[30–32]. Predefined predictors (sIL-2R and the total
HRCT score) were entered into a multivariable logistic
regression model with the PET result (positive versus
negative) as the dependent variable. As recommended
by prediction modeling guidelines, the preselected pre-
dictors remained in the model irrespective of statistical
significance [29].
To assess the performance of the final model, we quan-
tified its performance with respect to discrimination
and calibration. Discrimination is the model’s ability to
discriminate between PET-negative and PET-positive
patients, quantified as the area under the receiver operating
characteristic (ROC) curve [33]. This can range from
0.5 (no discrimination) to 1.0 (perfect discrimination).
Calibration is used to quantify the agreement between
the predicted probability and the actual, or observed,
frequencies. To this end, we computed the Hosmer and
Lemeshow (H-L) goodness-of-fit statistic. A high H-L
statistic will yield a low p-value and provides evidence
of lack of fit. As a measure of overall performance, we
computed the Brier score, which was scaled from 0 to
100%, so it could be interpreted as an r-squared statistic
of explained variance [34]. Statistical analyses were per-
formed using R (version 2.12.2; http://www.r-project.org).
Results
Table 1 shows a summary of relevant demographic and
clinical characteristics of the sarcoidosis patients (n = 95:
87 Caucasians, 5 of African origin and 3 of Asian origin)
categorized by the absence (n = 18: 19%) or presence
(n = 77: 81%) of positive PET findings. The PET-positive
group demonstrated significantly higher sIL-2R levels
(n= 77; 18 (18.9%) missing values) and total HRCT scores,
but lower DLCO values compared to the PET-negative
group. The number of patients with a chest radiography
(CXR) stage 0/I was higher in the PET-negative group.
In the PET-positive group, 56/77 (73%) patients showed
pulmonary PET-positive findings and 61/77 (79%) demon-
strated extrathoracic PET-positive findings.
Signs of fibrosis on HRCT were present in 26 patients.
Twenty-two (85%) of these patients had positive pulmonary
PET findings whereas only four (15%) had negative
pulmonary PET findings (p = 0.002). Median SUVmax
in the former patients was 7.1 (3.1-16.2). Extrathoracic
PET-positive findings were present in 18 (82%) and
positive serological inflammatory marker testing in 16
(73%), respectively, of those pulmonary PET-positive
patients with signs of fibrosis on HRCT.
Table 1 Clinical and demographic characteristics of the
sarcoidosis patients categorized by absence or presence
of positive PET findings
PET - patients PET+patients p-value
(n = 18) (n =77)
age (yrs) 46 (22-72) 45(24-76) 0.585
sex (male) 11 (61%) 44 (57%) 0.762
time since diagnosis
(yrs)
4 (1-20) 2 (1-21) 0.469
Therapy total,
number (%)
6 (33%) 20 (26%) 0.461
1/2/3/4 3/0/3/0 10/1/7/2 0.444
ACE (9-25 U/L) 15 (1-29) 18 (3-60) 0.136
sIL-2R (240-3154 pg/mL) 1784 (518-4614) 3434 (1191-15000) 0.002
Neopterin (<2.5 ng/mL) 1.7 (0.8-2.6) 2.8 (0.7-18.2) 0.030
CRP (2-9 μg/mL) 6 (1-15) 6 (1-80) 0.249
CXR stage 0/I 12/1 18/14 0.005
CXR stage II/III/IV 1/3/1 12/8/25 0.449
Total HRCT score 2.9 ± 3.0 6.0 ± 3.9 0.002
FVC total (% pred) 90 ± 22 91 ± 22 0.818
CXR I-II 94 ± 24 103 ± 15 0.174
CXR II-IV 79 ± 14 83 ± 22 0.741
DLCO total (% pred) 78 ± 18 69 ± 20 0.046
CXR I-II 79 ± 17 80 ± 17 0.888
CXR II-IV 71 ± 19 60 ± 19 0.234
Data are presented as median with range in parentheses; mean ± SD; absolute
numbers or percentages if appropriate. PET: positron emission tomography;
-: negative; +: positive; n:number; yrs: years; therapy total: total number of
patients treated at time of PET scanning; 1: prednisone monotherapy; 2:
methotrexate monotherapy; 3: prednisone and methotrexate combination
therapy; 4: methotrexate and infliximab combination therapy; ACE: serum
angiotensin-converting enzyme; sIL-2R: soluble interleukin-2 Receptor; CRP:
C-reactive protein; CXR: chest radiography; HRCT: high-resolution computed
tomography; FVC: forced vital capacity; % pred: percentage of predicted
values; DLCO: diffusion capacity for carbon monoxide. p < 0.05 was considered
to indicate significance.
Figure 1 Receiver operating characteristic (ROC) curve of the
model’s ability to discriminate between PET-negative and PET-
positive patients.
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Table 2 shows the regression coefficients and odds ratios
as derived from the original prediction model for the
probability of a positive PET result, and a validated modelTable 2 Regression coefficients and odds ratios with 95% con
the internally validated model
Original model
Variable Regression coefficient Odds ratio (95% C
Intercept -0.32 -
Elevated sIL-2R levels 1.98 7.27 (1.86 – 28.40)
Total HRCT score 0.24 1.27 (1.06 - 1.52)
To calculate the absolute risk of a positive PET result:P(PET-positive) = (1 / (1 + ex
CI: confidence interval; sIL-2R: soluble interleukin-2 Receptor; HRCT: high-resolution
* Regression coefficients after adjustment for overfitting by shrinkage (shrinkage facafter the bootstrap validation. The bootstrap validation
yielded a shrinkage factor of 0.93, which was used to
adjust the regression coefficients for overfitting. The
formula in table 2 allows predicted probabilities to be
calculated for future patients. Figure 1 shows the ROC
curve of the internally validated model. The area under
the curve was 0.83 (95% confidence interval (CI) = 0.74
– 0.93) indicating good discriminatory ability. Calibration
as quantified using the H–L goodness-of-fit test yielded a
p-value of 0.78, and the Brier score was 20.1%, indicating
both good calibration and good overall performance.
To improve feasibility of the prediction rule in clinical
practice, the rescaled regression coefficients for sIL-2R
and the total HRCT score were multiplied by 4 in order
to arrive at scores of 8 for a positive sIL-2R result and 1
per unit of the HRCT score, respectively. Hence, the
prediction rule score is based on sIL-2R results (0 pointsfidence intervals as derived from the original model and
Model after internal validation
I) p-value Regression coefficient* Odds ratio (95% CI)
- -0.23 -
0.004 1.85 6.33 (1.73-28.17)
0.011 0.22 1.25 (1.04-1.50)
p(-(-0.23 + 1.85 * sIL-2R+ 0.22 * HRCT score)))) * 100%
computed tomography; PET: positron emission tomography.
tor = 0.93); the intercept was re-estimated.
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total HRCT score (0-18 points). For example, the prediction
rule score for a patient with a positive sIL-2R result and a
total HRCT score of 5 would be 13 (8+5) points.
The implications of using the prediction rule in
clinical practice are shown in table 3. The right column
displays the number and percentage of patients that
would have an indication to be referred for PET using
consecutive cut-off points for the prediction rule score.
No data above a prediction rule score of 21 points are
displayed, since this was the highest prediction score
observed in the included patients. As this table shows,
a prediction rule score of ≥6 points (which can be
attained with a positive sIL-2R result only) is associated
with a positive predictive value of ≥91.0% for the presence
of inflammatory activity, whereas the negative predictive
value would be 42.9% in this case. If a positive predictive
value of ≥90% is considered acceptable for clinical
decision-making without referral to PET, only patients
with a score <6 (29.5% (28/95)) would have to be referredTable 3 Sensitivity, specificity, and positive and negative pre
points of the prediction rule score
Prediction rule
cut-off point*
Sensitivity (%)** Specificity (%)** Positive predicti
0 100 (77/77) 0 (0/18) 81 (77/95)
1 94.8 (73/77) 27.8 (5/18) 84.8 (73/86)
2 93.5 (72/77) 33.3 (6/18) 85.7 (72/84)
3 90.9 (70/77) 38.9 (7/18) 86.4 (70/81)
4 85.7 (66/77) 55.6 (10/18) 89.2 (66/74)
5 81.8 (63/77) 55.6 (10/18) 88.7 (63/71)
6 79.2 (61/77) 66.7 (12/18) 91.0 (61/76)
7 77.9 (60/77) 72.2 (13/18) 92.3 (60/65)
8 76.6 (59/77) 72.2 (13/18) 92.2 (59/64)
9 72.7 (56/77) 83.3 (15/18) 94.9 (56/59)
10 64.9 (50/77) 94.4 (17/18) 98.0 (50/51)
11 53.2 (41/77) 94.4 (17/18) 97.6 (41/42)
12 48.1 (37/77) 94.4 (17/18) 97.4 (37/38)
13 41.6 (32/77) 94.4 (17/18) 97.0 (32/33)
14 35.1 (27/77) 94.4 (17/18) 96.4 (27/28)
15 27.3 (21/77) 100 (18/18) 100 (21/21)
16 24.6 (19/77) 100 (18/18) 100 (19/19)
17 20.8 (16/77) 100 (18/18) 100 (16/16)
18 13.0 (10/77) 100 (18/18) 100 (10/10)
19 7.8 (6/77) 100 (18/18) 100 (6/6)
20 7.8 (6/77) 100 (18/18) 100 (6/6)
21 3.9 (3/77) 100 (18/18) 100 (3/3)
*Patients were considered test-positive if the prediction rule score was at or above
**Data in parentheses represent proportions.
***Number of patients that would have been indicated for referral to PET if the prefor PET (table 3, right column). Using a somewhat higher
cut-off value of ≥10 points yields a positive predictive
value ≥98%, and about half of the patients (46.3%) would
require referral to PET.
Figure 2 provides a graphical representation of the
predicted values and their 95% CIs. The probability can
also be calculated using the formula given in table 2.Discussion
In the present study, we developed an internally vali-
dated clinical prediction rule that appeared to be useful
to identify symptomatic sarcoidosis patients in whom
the presence of inflammatory activity is highly likely.
This clinical prediction rule is based on sIL-2R (positive/
negative) and HRCT results. Inflammatory activity was
regarded as present if PET findings were positive.
To the best of our knowledge, this is the first clinical
prediction rule to predict inflammatory activity in sar-
coidosis patients that has been constructed according todictive values for PET-positivity at consecutive cut-off
ve value (%)** Negative predictive value (%)** Patients referred
for PET (%)***
- 0 (/95)
55.5 (5/9) 9.5 (9/95)
54.5 (6/11) 11.6 (11/95)
50.0 (7/14) 14.7 (14/95)
47.6 (10/21) 22.1 (21/95)
41.7 (10/24) 25.3 (24/95)
42.9 (12/28) 29.5 (28/95)
43.3 (13/30) 31.6 (30/95)
41.9 (13/31) 32.6 (31/95)
41.7 (15/36) 37.9 (36/95)
38.6 (17/44) 46.3 (44/95)
32.0 (17/53) 55.8 (53/95)
29.8 (17/57) 60.0 (57/95)
27.4 (17/62) 65.3 (62/95)
25.4 (17/67) 70.5 (67/95)
24.3 (18/74) 77.9 (74/95)
23.7 (18/76) 80.0 (76/95)
22.8 (18/79) 83.2 (79/95)
21.2 (18/85) 89.5 (85/95)
20.2 (18/89) 93.7 (89/95)
20.2 (18/89) 93.7 (89/95)
19.6 (18/92) 96.8 (92/95)
this level.
diction rule score was at or above the corresponding level.
Figure 2 Predicted probability of inflammatory activity being
detected by PET in sarcoidosis patients as a function of the
prediction rule score.
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rules.
In general, assessment of inflammatory activity is vital
in the management of sarcoidosis, and is especially ne-
cessary to monitor the course of sarcoidosis and guide
therapeutic strategies [3–5]. The presence of inflammatory
activity is considered to indicate persistent evolution of
the disease and may therefore be a target for therapy.
The presence of inflammatory activity can be regarded
as certain in case CXR findings or lung function test
results provide evidence of disease progression [4].
However, the management of patients with non organ
specific persistent disabling symptoms requires reliable
and clinically useful markers of inflammatory activity.
PET has been shown to be a very sensitive technique to
assess inflammatory activity in sarcoidosis [7,17–20].
Several reports demonstrated a significant reduction of
FDG uptake after the initiation or modification of
treatment in sarcoidosis patients [5,17,18,35,36]. Keijsers
et al. [5] demonstrated that changes in PET imaging in a
small cohort of sarcoidosis patients treated with infliximab
correlated with clinical improvement. Another study
showed that diffuse pulmonary parenchymal activity
in sarcoidosis patients, as imaged by 18 F-FDG PET,
predicted a future deterioration of DLCO when medical
treatment was withheld, while treatment significantly
improved lung function [24].In the present study, a high frequency of both pulmonary-
and extrathoracic PET-positivity as well as serological
signs of inflammatory activity was established in the
majority of patients. Even most sarcoidosis patients
with signs of pulmonary fibrosis demonstrated positive
pulmonary PET findings and extrathoracic PET-positive
findings (82%) and increased serological inflammatory
markers (73%). These findings strongly suggest that
PET-positive findings in sarcoidosis patients with CXR
stage IV are related to inflammatory activity.
This supports the value of PET, even in patients with
signs of pulmonary fibrosis [8,23]. Deciding which sar-
coidosis patients with signs of pulmonary fibrosis may
benefit from pharmacological treatment remains a
challenge to clinicians, as it is not always clear whether
respiratory symptoms in these patients are a result of
organ damage or due to ongoing inflammation or both.
To date, there is no medication with the capability of
reversing fibrosis, but treatment might arrest fibrosis
of reversible granulomas that persist among the fibrotic
elements [37]. Teirstein et al. [17] reported a response to
therapy in PET-positive patients, including patients
with radiographic stage IV, with partial clearing of the
parenchymal radiographic abnormalities, improvement
in pulmonary function and decreased hypermetabolism
by repeated PET. Furthermore, detecting extrathoracic
inflammatory lesions may also provide an explanation
for (mainly extrathoracic) symptoms [8].
The question can be raised which patients might benefit
from having a PET scan [21,22]. Until now, there have
been no guidelines for selecting those patients with non
organ specific persistent disabling symptoms for whom
PET might offer added value in the assessment of inflam-
matory activity. The prediction rule developed in the
present study proved to be able to distinguish between
patients with positive and negative PET findings. Applying
this simple prediction rule quantifies the probability that
inflammatory activity will be established by PET. As
presented in table 3, PET would only be indicated in
less than one third of the patients in our study if a positive
predictive value for the presence of inflammatory activity
(PET-positivity) of ≥90% is considered acceptable for
clinical decision making without referral to PET. This
predictive value was reached with a positive sIL-2R
result alone (8 points; positive predictive value 92.2%).
Among patients with a normal sIL-2R level, PET
appeared only to be indicated in those with a total
HRCT score of <6 points (positive predictive value
<90%). If a positive predictive value of approximately
100% is considered desirable, a cut-off value of <10
points can be used (positive predictive value <98%) in
deciding whether to refer patients to PET. In this case,
referral to PET would be indicated in about half of the
patients.
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a PET might be indicated can help to reduce the number
of PET scans. This may result in considerable cost
reductions, as only a limited number of tests have to be
used and these tests are far less expensive than PET. In
addition, our prediction rule represents the first attempt
to standardize the assessment of inflammatory activity in
sarcoidosis.
It should be noted that this rule has been developed in
a sample of sarcoidosis patients with non organ specific
persistent disabling symptoms. It was derived from and
validated in patients from a single referral centre for
sarcoidosis, which could limit the generalization of these
results. Hence, validation of this prediction rule in other,
and larger, sarcoidosis patient populations is warranted.
We used bootstrap validation for the internal validation,
and adjusted the regression coefficients using the shrinkage
factor. Prospective evaluation of the prediction rule in
the future should use the internally validated model as
described in table 2.
In conclusion, the derived and internally validated
clinical prediction rule, based on sIL-2R levels and
HRCT scoring results, appeared to be useful to identify
sarcoidosis patients with a high probability of inflammatory
activity. Hence, using this rule may be helpful to identify
sarcoidosis patient in whom a PET might be of additional
value to assess inflammatory activity. These results may
affect patient care by providing supportive evidence for
more effective use of PET scan in the assessment of
inflammatory activity in sarcoidosis.Table 4 Definition of abnormal high-resolution computed tom
Oberstein et al. [27], visual score
Lung volume affect
No lesions: 0









BVB: thickening or irregularity of the bronchovascular bundle; PC: parenchymal con
nodules; LS: septal and nonseptal lines; PL: focal pleural thickening; LN: enlargemen
The total score is obtained by adding up the individual scores (BVB, ND, LS, PC, LN,
a The lung volume affected is quantified by a visual score: 0 = no lesions found; 1 =
66%; and 3 =more than 66% of the volume affected.
b The PL and the enlargement of the LN (with a short axis of 1 cm or more conside
2 =moderate; and 3 = pronounced changes.
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solidation (including ground-glass opacifications); ND: intraparenchymal
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red enlarged) is quantified: 0 = no pathological findings; 1 =minor;
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